Update on iron supplementation in patients with cancer-related anemia

References

• Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia. Am J Hematol. 2014;89(2):203–212. doi: 10.1002/ajh.23628
   PubMed Web of Science ®Google Scholar
• Andrews NC. Forging a field: the golden age of iron biology. Blood. 2008;112(2):219–230. doi: 10.1182/blood-2007-12-077388
   PubMed Web of Science ®Google Scholar
• Pantopoulos K, Porwal SK, Tartakoff A, et al. Mechanisms of mammalian iron homeostasis. Biochemistry. 2012;51(29):5705–5724. doi: 10.1021/bi300752r
   PubMed Web of Science ®Google Scholar
• Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. Blood. 2020;136(7):801–813. doi: 10.1182/blood.2019004017
   PubMed Web of Science ®Google Scholar
• Camaschella C. Disorders of iron homeostasis: iron deficiency and overload. In: Hoffman R, Benz E, Silverstein L, et al., editors. Hematology: basic principles and practice. 8th ed. Philadelphia: Elsevier; 2023. p. 483–497.
   Google Scholar
• Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90(1):12–23. doi: 10.1016/j.mayocp.2014.10.007
   PubMed Web of Science ®Google Scholar
• Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter open-label, randomized trial. JCO. 2004;24(7):1301–1307. doi: 10.1200/JCO.2004.08.119
   Google Scholar
• Rodgers GM, Gilreath JA. The role of intravenous iron in the treatment of anemia associated with cancer and chemotherapy. Acta Haematol. 2019;142(1):13–20. doi: 10.1159/000496967
   PubMed Web of Science ®Google Scholar
• Kim YT, Kim SW, Yoon BS, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol. 2007;105(1):199–204. doi: 10.1016/j.ygyno.2006.11.014
   PubMed Web of Science ®Google Scholar
• Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol. 2010;116(3):522–525. doi: 10.1016/j.ygyno.2009.12.004
   PubMed Web of Science ®Google Scholar
• Abdel-Razeq H, Abbasi S, Saadi I, et al. Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study. Drug Des Devel Ther. 2013;7:939–944. doi: 10.2147/DDDT.S45674
   PubMed Web of Science ®Google Scholar
• Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum based chemotherapy. Gynecol Oncol. 2013;131(3):679–682. doi: 10.1016/j.ygyno.2013.09.028
   PubMed Web of Science ®Google Scholar
• Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer-and chemotherapy-associated anaemia. Ann Oncol. 2013;24(2):475–482. doi: 10.1093/annonc/mds338
   PubMed Web of Science ®Google Scholar
• Hedenus M, Karlsson T, Ludwig H, et al. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med Oncol. 2014;31(12):302. doi: 10.1007/s12032-014-0302-3
   PubMed Web of Science ®Google Scholar
• Birgegard G, Henry D, Glaspy J, et al. A randomized noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: the PROFOUND trial. Pharmacotherapy. 2016;36(4):402–414. doi: 10.1002/phar.1729
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Dahl NV, Bernard K, et al. Efficacy and safety of IV ferumoxytol for iron deficiency anemia in patients with cancer. J Blood Med. 2017;8:199–209. doi: 10.2147/JBM.S138474
   PubMed Web of Science ®Google Scholar
• Jang JH, Kim Y, Park S, et al. Efficacy of intravenous iron treatment for chemotherapy-induced anemia: a prospective phase II pilot clinical trial in South Korea. PLoS Med. 2020;17(6). doi: 10.1371/journal.pmed.1003091
   PubMed Web of Science ®Google Scholar
• Makharadze T, Boccia R, Krupa A, et al. Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: a randomized, p lacebo-controlled study (IRON - CLAD). Am J Hematol. 2021;96(12):1639–1646. doi: 10.1002/ajh.26376
   PubMed Web of Science ®Google Scholar
• Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007;21(4):627–632. doi: 10.1038/sj.leu.2404562
   PubMed Web of Science ®Google Scholar
• Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncology. 2007;12(2):231–242. doi: 10.1634/theoncologist.12-2-231
   Google Scholar
• Bastit L, Vandebroek A, Altintas S, et al. Randomized multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;26(10):1611–1618. doi: 10.1200/JCO.2006.10.4620
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008;26(10):1619–1625. doi: 10.1200/JCO.2007.12.2051
   PubMed Web of Science ®Google Scholar
• Auerbach M, Silberstein PT, Webb RT, et al. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol. 2010;85(9):655–663. doi: 10.1002/ajh.21779
   PubMed Web of Science ®Google Scholar
• Steensma DP, Sloan JA, Dakhil SR, et al. Phase III randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol. 2011;29(1):97–105. doi: 10.1200/JCO.2010.30.3644
   PubMed Web of Science ®Google Scholar
• Rodgers GM, Auerbach M, Cella D, et al. High-molecular weight iron dextran: a wolf in sheep’s clothing? J Am Soc Nephrol. 2008;19(5):833–834. doi: 10.1681/ASN.2008030255
   PubMed Web of Science ®Google Scholar
• Dave CV, Brittenham GM, Carson JL, et al. Risks for anaphylaxis with intravenous iron formulations. A retrospective cohort study. Ann Intern Med. 2022;175(5):656–664. doi: 10.7326/M21-4009
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Glaspy JA, Means RT, et al. Risks for anaphylaxis with intravenous iron formulations. Ann Intern Med. 2022;175(11):W143. doi: 10.7326/L22-0282
   PubMedGoogle Scholar
• Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol. 2020;13(2):187–195. doi: 10.1080/17474086.2020.1709437
   PubMed Web of Science ®Google Scholar
• Arastu AH, Elstrott BK, Martens KL, et al. Analysis of adverse events and intravenous iron infusion formulations in adults with and without prior infusion reactions. JAMA Netw Open. 2022;5(3):e224488. doi: 10.1001/jamanetworkopen.2022.4488
   PubMed Web of Science ®Google Scholar
• Griffiths EA, Roy V, Bachiashvili K, et al. Hematopoietic growth factors. NCCN guidelines version 3. 2024 [cited 2024 May 11]. Available from: nccn.org
   Google Scholar
• Bohlius J, Bohkle K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019;3(8):1197–1210. doi: 10.1182/bloodadvances.2018030387
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PH, Cohen H. Serious hazards of transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol. 2013;163(3):303–314. doi: 10.1111/bjh.12547
   PubMed Web of Science ®Google Scholar
• Hendrickson JE, Roubinian NH, Chowdhury D, et al. Incidence of transfusion reactions: a multicenter study utilizing systemic active surveillance and expert adjudication. Transfusion. 2016;56(10):2587–2596. doi: 10.1111/trf.13730 13730.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168(21):2377–2381. doi: 10.1001/archinte.168.21.2377
   PubMedGoogle Scholar
• Jahn MR, Andreasen HB, Futterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78(3):480–491. doi: 10.1016/j.ejpb.2011.03.016
   PubMed Web of Science ®Google Scholar
• Alsaleh NB, Brown JM. Engineered nanomaterials and type 1 allergic hypersensitivity reactions. Front Immunol. 2020;11: Article 222, 1–14. doi: 10.3389/fimmu.2020.00222
   PubMed Web of Science ®Google Scholar
• Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reaction to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671–1676. doi: 10.3324/haematol.2014.111492
   PubMed Web of Science ®Google Scholar
• Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996;28(4):529–534. doi: 10.1016/S0272-6386(96)90463-1
   PubMed Web of Science ®Google Scholar
• Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007;369(9572):1502–1504. doi: 10.1016/S0140-6736(07)60689-8
   PubMed Web of Science ®Google Scholar
• Montandon SV, Fajt ML, Petrov AA. A safe and novel desensitization protocol with ferric carboxymaltose to treat iron deficiency anemia. Curr Drug Saf. 2016;11(2):145–148. doi: 10.2174/1574886311666151209114203
   PubMedGoogle Scholar
• Steinmetz T, Schroder J, Plath M, et al. Antianemic treatment of cancer patients in German routine practice: data from a prospective cohort study—the tumor anemia registry. Anemia. 2016;2016:1–9. doi: 10.1155/2016/8057650
   Google Scholar
• Hufnagel DH, Mehta ST, Ezekwe C, et al. Prevalence of anemia and compliance with NCCN guidelines for evaluation and treatment of anemia in patients with gynecologic cancer. J Natl Compr Canc Netw. 2021;19:513–520. doi: 10.6004/jnccn.2020.7638
   PubMed Web of Science ®Google Scholar
• Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl 4):iv96–iv110. doi: 10.1093/annonc/mdx758
   PubMed Web of Science ®Google Scholar
• De Loughery TG. Safety of oral and intravenous iron. Acta Haematol. 2019;142(1):8–12. doi: 10.1159/000496966
   PubMed Web of Science ®Google Scholar
• Kelsey SM, Hider RC, Bloor JR, et al. Absorption at low and therapeutic doses of ferric maltol, a novel ferric iron compound, in iron-deficient subjects using a single dose iron absorption test. J Clin Pharm Ther. 1991;16(2):117–122. doi: 10.1111/j.1365-2710.1991.tb00292.x
   PubMed Web of Science ®Google Scholar
• Pergola PE, Kopyt NP. Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: a randomized trial and open-label extension. AJKD. 2021;78(6):846–856. doi: 10.1053/j.ajkd.2021.03.020
   PubMed Web of Science ®Google Scholar
• Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21:579–588. doi: 10.1097/MIB.0000000000000314
   PubMed Web of Science ®Google Scholar
• Howaldt S, Domenech E, Martinez N, et al. Long term effectiveness of oral ferric maltol vs intravenous ferric carboxylmaltose for the treatment of iron-deficiency anemia in patients with inflammatory bowel disease: a randomized controlled noninferiority trial. Inflamm Bowel Dis. 2022;28(3):373–384. doi: 10.1093/ibd/izab073
   PubMed Web of Science ®Google Scholar
• Gomez-Ramirez S, Brilli E, Tarantino G, et al. Sucrosomial® iron: an updated review of its clinical efficacy for the treatment of iron deficiency. Pharmaceuticals (Basel). 2023;16(6):847. doi: 10.3390/ph16060847
   PubMedGoogle Scholar
• Pantopoulos K. Oral iron supplementation: new formulations, old questions. Haematologica. 2024 Apr 11. doi: 10.3324/haematol2024.284967
   PubMedGoogle Scholar
• Mueller MM, van Remoortel H, Meybohm P, et al. Patient blood management: recommendations from the 2018 Frankfurt consensus conference. JAMA. 2019;321(10):983–997. doi: 10.1001/jama.2019.0554
   PubMed Web of Science ®Google Scholar
• Fein S, Alonso D, Menendez M, et al. Overcoming the obstacles that prevent identification and treatment of women who have iron deficiency. In: Abstracts of the American Society of Hematology; 2023 Dec; San Diego, CA USA. 2023.
   Google Scholar
• Steensma DP, Sloan JA, Loprinzi CL. Reply to M. Aapro et al. J Clin Oncol. 2011;29(17):e527–528. doi: 10.1200/JCO.2011.35.4597
   Google Scholar